Literature DB >> 12167464

Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor.

John C Anthes1, Helen Gilchrest, Christian Richard, Stephen Eckel, Dave Hesk, Robert E West, Shirley M Williams, Scott Greenfeder, Motasim Billah, William Kreutner, Robert E Egan.   

Abstract

We have characterized desloratadine (5H-benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene), CAS 100643-71-8) as a potent antagonist of the human histamine H(1) receptor. [3H]Desloratadine bound to membranes expressing the recombinant human histamine H(1) receptor in Chinese hamster ovary cells (CHO-H(1)) in a specific and saturable manner with a K(d) of 1.1+/-0.2 nM, a B(max) of 7.9+/-2.0 pmol/mg protein, and an association rate constant of 0.011 nM(-1) x min(-1). The K(d) calculated from the kinetic measurements was 1.5 nM. Dissociation of [3H]desloratadine from the human histamine H(1) receptor was slow, with only 37% of the binding reversed at 6 h in the presence of 5 microM unlabeled desloratadine. Seventeen histamine H(1)-receptor antagonists were evaluated in competition-binding studies. Desloratadine had a K(i) of 0.9+/-0.1 nM in these competition studies. In CHO-H(1) cells, histamine stimulation resulted in a concentration-dependent increase in [Ca(2+)](i) with an EC(50) of 170+/-30 nM. After a 90-min preincubation with desloratadine, the histamine-stimulated increase in [Ca(2+)](i) was shifted to the right, with a depression of the maximal response at higher concentrations of antagonist. The apparent K(b) value was 0.2+/-0.14 nM with a slope of 1.6+/-0.1. The slow dissociation from the receptor and noncompetitive antagonism suggests that desloratadine may be a pseudoirreversible antagonist of the human histamine H(1) receptor. The mechanism of desloratadine antagonism of the human histamine H(1) receptor may help to explain the high potency and 24-h duration of action observed in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167464     DOI: 10.1016/s0014-2999(02)02049-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

Review 1.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 3.  The safety and efficacy of desloratadine for the management of allergic disease.

Authors:  William E Berger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  How were new medicines discovered?

Authors:  David C Swinney; Jason Anthony
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

5.  Characterization of 12 GnRH peptide agonists - a kinetic perspective.

Authors:  Indira Nederpelt; Victoria Georgi; Felix Schiele; Katrin Nowak-Reppel; Amaury E Fernández-Montalván; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2015-11-04       Impact factor: 8.739

Review 6.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Selecting the optimal oral antihistamine for patients with allergic rhinitis.

Authors:  Jeffrey M Lehman; Michael S Blaiss
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine.

Authors:  Nelly Frossard; Margherita Strolin-Benedetti; Ashok Purohit; Gabrielle Pauli
Journal:  Br J Clin Pharmacol       Date:  2007-10-29       Impact factor: 4.335

Review 9.  Desloratadine: an update of its efficacy in the management of allergic disorders.

Authors:  David Murdoch; Karen L Goa; Susan J Keam
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.

Authors:  Philippe Devillier; Nicolas Roche; Christophe Faisy
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.